Extending Immunotherapy for Metastatic Melanoma
Name of the Trial
Why This Trial Is Important
In adoptive cell transfer, tumor-infiltrating T lymphocytes, or TILs, are harvested from a patient's tumor(s), and the cancer-fighting properties of these cells are enhanced in the laboratory. The TILs are subsequently expanded (grown) to increase their numbers and then injected back into the patient. Adoptive cell transfer for melanoma focuses on TILs that target an antigen called MART-1, which is found on melanoma cells.
Tumor-reactive TILs cannot be obtained, however, from many patients. Thus, researchers have developed techniques to genetically engineer a patient's T lymphocytes to express the receptor protein that recognizes and binds to MART-1. The modified cells are then grown and infused into the patient.
This study will involve two groups of patients. One group will receive TILs containing transferred genes for the MART-1 receptor; the second group will receive T lymphocytes isolated from blood that also contain added MART-1 receptor genes.
"If these genetically engineered cells prove safe and show antitumor activity," said Dr.Rosenberg, "we plan to create lymphocytes that can target more common malignancies, including breast and colorectal cancers. There is tremendous potential here."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.